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To my family
  
ABSTRACT 
Frontotemporal dementia (FTD) is the second most common form of 
neurodegenerative disease affecting people under the age of 65 years. The general 
symptoms are dysfunctions in behavior and/or language. Up to 50 % of FTD patients 
have a positive family history for dementia and mutations in the progranulin (GRN) 
gene account for 13-25 % of the familial cases. In Paper I, the Swedish Karolinska 
family with FTD was shown to have a GRN mutation, p.Gly35GlufsX19, which 
segregated with the disease. The mutation resulted in an ~50 % reduction of the GRN 
transcript. Sequencing the GRN cDNA resulted in only wild type sequence indicating 
that the mutant allele had been degraded resulting in reduced GRN transcript levels.  
GRN mutations have reduced penetrance which is shown e.g. in the 
Karolinska family where there is a 10 years range in age at onset. The single nucleotide 
polymorphism (SNP) rs1990622, in linkage disequilibrium with the transmembrane 
protein 106B (TMEM106B) gene, was suggested to modify age at onset in GRN 
mutations carriers. In Paper II, the effect of rs1990622 on age at onset in four GRN 
mutation families, including the Karolinska family was investigated. Patients 
homozygous for the A allele were shown to have a significantly earlier (13 years) 
median age at onset compared to patients with the GA or GG genotype. To investigate 
possible disease mechanisms of rs1990622, the GRN levels in plasma and the 
TMEM106B mRNA levels in brain tissue were measured. An effect of rs1990622 
genotype on plasma-GRN levels was detected with AA carriers having the lowest GRN 
levels and GG carriers the highest levels. However, this effect was not shown to be 
mediated by the modulation of TMEM106B transcript levels.   
In Paper III, 100 FTD patients from Sweden were screened for GRN 
mutations and four premature stop codon mutations were identified: p.Gly35GlufsX19, 
p.Cys416LeufsX30, p.Tyr294X and p.Cys404X. Furthermore, the p. Cys416LeufsX30 
was shown to segregate in a family with clinical heterogeneity. The serum-GRN levels 
in carriers of the three first premature stop codons showed a more than 50 % reduction 
compared to non-carriers. GRN levels and age at onset in the patient cohort varied and 
were thus investigated for association with rs1990622, rs5848 (located in the 3’UTR of 
GRN) and apolipoprotein E (APOE). Patients with the TT genotype at rs5848 had 
significantly lower GRN levels compared to CT and CC genotypes. Moreover, APOE 
ɛ4 positive patients had a significantly later age at onset compared to ɛ4 negative 
patients.  
FTD and amyotrophic lateral sclerosis (ALS) are part of the same disease 
spectrum. The identification of TAR DNA binding protein 43 (TDP-43) positive 
neuronal inclusions in the majority of ALS and FTD patients further supported the link. 
To investigate the importance of TARDBP (the gene encoding TDP-43) mutations in 
Nordic ALS patients, 177 patients were sequenced in Paper IV. Four missense 
variations in three familial ALS patients were detected: p.Ala90Val, p.Gly357Arg, 
p.Arg361Thr and p.Ser379Pro. The three last missense variations were concluded to be 
possibly pathogenic since they were predicted by in silico analysis to be pathogenic and 
were absent in 200 neurologically healthy controls. The mutation frequency of 
TARDBP in Nordic ALS patient was 1.7 %. Furthermore, the p.Arg361Thr was shown 
to be present in a family with both ALS and FTD-ALS which further strengthens the 
connection between FTD and ALS. 
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INTRODUCTION 
 
For many neurodegenerative diseases the disease mechanisms are unknown. In order to 
get an insight of the underlying pathogenic mechanisms, familial forms of different 
neurodegenerative diseases are studied. In a family where there is a dominant 
inheritance pattern, the disease could be caused by a mutation in a gene. By identifying 
the gene and elucidating its function another piece of the disease mechanism puzzle 
will be obtained. However, even if the same gene is mutated the consequences can be 
quite different, including clinical heterogeneity and different onset ages. This simply 
demonstrates that there are other genetic and/or environmental factors that can modify 
the disease. The two neurodegenerative diseases studied in this thesis are 
frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). They involve 
different parts of the nervous system and the main symptoms differ between them. 
However, they are recognized to be two extremes in one disease spectrum with 
overlapping clinical, genetic and neuropathological characteristics.  
 
In this thesis focus has been placed on two genes, one of which is the progranulin 
(GRN) gene. GRN is one of the most frequently mutated genes in FTD. It is recognized 
that GRN mutations have reduced penetrance and result therefore in varied ages at 
onset. Different modifying genes for age at onset in FTD patients have been suggested 
but the evidence has not been conclusive. Three potential modifying factors have been 
investigated in this thesis: apolipoprotein E (APOE); rs5848 in the 3’ untranslated 
region (UTR) of GRN; and rs1990622, a polymorphism located ~6.9 kbp from and in 
linkage disequilibrium (LD) with the transmembrane protein 106B gene (TMEM106B). 
Neuropathological examinations of GRN mutation carriers show neuronal inclusions 
immunoreactive for the protein TAR DNA-binding protein 43 (TDP-43). 
Approximately 50 % of all FTD patients have neuronal inclusions positive for TDP-43 
(FTLD-TDP) which makes it the largest neuropathological subgroup in frontotemporal 
lobar degeneration (FTLD). There have been a few reports about FTD patients carrying 
mutations in TARDBP, the gene encoding TDP-43. However, mutations in TARDBP 
have primarily been reported in ALS patients. In addition, the majority (more than  
90 %) of ALS patients also have neuronal inclusions positive for TDP-43. Thus, the 
TDP-43 protein ties FTD and ALS closer together. In order to determine the impact of 
TARDBP mutations in Nordic ALS patients, the TARDBP gene has also been studied in 
this thesis. 
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FRONTOTEMPORAL DEMENTIA  
In the literature frontotemporal dementia (FTD) and frontotemporal lobar degeneration 
(FTLD) have been used either to differentiate between the clinical diagnosis (FTD) and 
the neuropathological diagnosis (FTLD) or used as a collective term that does not 
differentiate between the clinical and neuropathological diagnosis (FTLD). Here FTD 
will be used as the umbrella term for all clinical subgroups and FTLD as the collective 
term for all neuropathological subgroups.  
 
FTD is the second most common form of neurodegenerative disease mainly affecting 
people under the age of 65 years. It is a heterogeneous disease and there are three major 
clinical subgroups: behavior variant FTD (bvFTD), progressive non-fluent aphasia 
(PNFA) and semantic dementia (SD) 
1
. Patients with bvFTD have primarily changes in 
behavior such as social disinhibition, lack of initiative and insight. Patients diagnosed 
as PNFA or SD have instead mainly language dysfunctions. PNFA patients have 
primary symptoms such as effortful speech, word retrieval difficulties, phonological 
and grammatical errors. Early in the disease the patient still understands relatively well 
the meaning of the words even if the patient has difficulties in retrieving words. In 
contrast, patients with SD do not understand the meaning of the words and have 
effortless but empty speech. Most patients have bvFTD but patients diagnosed with 
FTD can, as the disease progresses, develop both behavior changes and language 
dysfunction. In addition, some patients develop motor symptoms such as parkinsonism 
(16 %) or ALS (7-15 %) 
2
. The age at onset is usually between 50-60 years and has a 
wide range from before 30 years to after 75 years. The mean disease duration is 6-8 
years but can range from 2-20 years, which is partly due to different underlying 
pathologies e.g. FTD patients who also develop ALS have a mean survival of 2-3 years 
1-8
. 
 
 
NEUROPATHOLOGY 
Neuropathological examination of FTD patients typically shows bilateral or unilateral 
atrophy of the frontal and/or temporal lobes. Patients with bvFTD usually have 
symmetrical frontal and anterior temporal atrophy while patients with PNFA usually 
have asymmetric atrophy, involving mainly the left frontotemporal lobes and SD 
patients have bilateral atrophy of the anterior temporal lobe, typically left more than 
right. In most FTLD cases microvacuolation and neuronal loss are observed around 
layer II of the cerebral cortex. There are four different neuropathological subgroups of 
FTLD that can be distinguished using immunohistochemical methods which are 
described below (Figure 1) 
6, 9-13
.  
 
 FTLD-TDP: dystrophic neurites, neuronal cytoplasmic inclusions (NCIs), 
neuronal intranuclear inclusions (NIIs) and glial cytoplasmic inclusions 
immunoreactive for TDP-43 in the superficial layers of frontal and temporal 
neocortex and neurons of the dentate gyrus in the hippocampus. The aggregated 
TDP-43 protein is hyperphosphorylated, ubiquitinated (ub) and C-terminally 
fragmented. FTLD-TDP is the largest subgroup and accounts for ~50 % of all 
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FTLD cases. This group can further be classified into four histological 
subgroups 
14
: 
 Type A: numerous NCIs, dystrophic neurites and variable numbers of 
NIIs located predominantly in the superficial cortical layers. GRN 
mutation carriers typically have type A histology.  
 Type B: moderate NCIs in both superficial and deep cortical layers, few 
dystrophic neurites and few or no NIIs. 
 Type C: numerous long dystrophic neurites and few or no NCIs and 
NIIs, which are mostly found in the neocortex in the superficial layers.  
 Type D: numerous NIIs and dystrophic neurites and few NCIs in the 
cortex with relative sparing of the hippocampus. This histological 
subtype is characteristic for valosin containing protein (VCP) mutation 
carriers. 
 FTLD-tau: neurites, NCI and glial cytoplasmic inclusions immunoreactive for 
ub and hyperphosphorylated microtubule associated protein tau. Different types 
of tau positive inclusions can be observed such as Pick bodies and 
neurofibrillary tangles with paired helical filaments and straight filaments in 
wide distribution in the cerebrum, cerebellum and brain stem.  
 FTLD-FUS: NCI, NII, glial cytoplasmic inclusions and dystrophic neurites are 
negative for TDP-43 and immunoreactive for ub and fused in sarcoma (FUS) 
protein in the frontal and temporal cortex and hippocampus.  
 FTLP-UPS: FTLD patients have NCIs immunoreactive for proteins in the 
ubiquitin proteasome system (UPS) such as ub and p62, and negative for tau, 
TDP-43 and FUS in the frontal and temporal lobes and dentate gyrus in the 
hippocampus. Thus, the identity of the ub and aggregated proteins is still 
unknown.   
 
The neuropathological subgroups are present in different frequencies with FTLD-TDP 
being the most common: FTLD-TDP > FTLD-tau >>> FTLD-FUS > FTLD-UPS 
5, 6, 9-
13
. It is not possible to predict the neuropathological subtype based on the clinical 
symptoms. However, for patients with FTLD-FUS neuropathology (representing ~5 % 
of all FTLD cases) it has been reported that they have more severe and aggressive 
disease progression with younger age at onset (≤40 years) and severe caudate atrophy 
Figure 1. A schematic figure of the four neuropathological subgroups of FTLD 
and the genes associated with these subgroups in italics.  
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compared to the other neuropathological subgroups. Furthermore, FTLD-FUS patients 
usually do not have a family history for dementia 
13, 15
.  
 
Neuropathological examination of patients who presents both FTD and ALS usually 
have FTLD-TDP pathology together with TDP-43 and ub-immunoreactive inclusions 
in the lower motor neurons (brain stem and spinal cord) 
16, 17
. 
 
FTD GENETICS 
Up to 50 % of all FTD cases have a positive family history of dementia indicating that 
genetic factors are contributing to the etiology 
5, 18, 19
. There have been major 
discoveries in FTD genetics the last five years 
20-27
. Through linkage analysis and target 
gene sequencing seven genes have today been described to carry mutations that can 
result in FTD and FTD related syndromes:  
 
 TAR DNA-binding protein 43 (TARDBP) in chromosome 1p36.22 28-31 
 charged multivesicular body protein 2B (CHMP2B) in chromosome 3p12.1 32 
 valosin containing protein (VCP) in chromosome 9p13 33 
 chromosome 9 open reading frame 72 (C9orf72) in chromosome 9p21.1 22, 24 
 fused in sarcoma (FUS) in chromosome 16p11.2 34, 35 
 progranulin (GRN) in chromosome 17q21.32 20, 21 
 microtubule-associated protein tau (MAPT) in chromosome 17q21 36 
 
FTD patients with different mutations have different histological and neuropathological 
subdiagnoses which suggest that there are different disease mechanisms (Figure 1). Of 
these seven genes, mutations in MAPT, GRN and C9orf72 are the most common but 
there are no clinical symptoms that can distinguish these different mutation carriers 
from each other. Mutations in VCP and CHMP2B have only been detected in a few 
families and families with rare FTD subtypes such as Inclusion body myopathy with 
Paget disease of bone and frontotemporal dementia. Mutations in TARDBP and FUS 
were first discovered in ALS patients but were later shown to be present in a few 
patients with FTD and FTD-ALS.  
 
Microtubule-associated protein tau – MAPT  
The MAPT gene was the first major gene which was shown to carry causative 
mutations for FTD. Mutations in MAPT have been detected in 5-10 % of all FTD 
patients and so far, 44 MAPT mutations have been reported. The majority is located in 
exons 9-13 and in intron 10 (http://www.molgen.ua.ac.be/FTDMutations). Mutations in 
exon 10 and intron 10 mainly affect the normal splicing of exon 10, which leads to the 
retention of exon 10 and thus more 4-repeat tau isoform. This increase of 4-repeat tau 
isoform will result in a shift in the ratio between 3-repeat (splicing out of exon 10) and 
4-repeat (retention of exon 10) tau isoforms. The main function of the tau protein is to 
stabilize and promote microtubule assembly by binding to tubulin. The 4-repeat tau has 
stronger binding affinity to tubulin compared to 3-repeat tau 
37-39
. The shift of 3- and 4-
repeat tau ratio could have consequences in the normal dynamics of microtubule 
assembly. Almost all missense mutations have an effect on microtubule assembly 
probably by interfering with the interaction between tau and tubulin, and thereby 
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decreasing the ability of tau to promote microtubule assembly 
36, 38, 40, 41
. The mean age 
at onset for MAPT mutation carriers is 55 years (range 45-65 years) and most mutation 
carriers develop the disease before 65 years of age. Patients carrying MAPT mutations 
usually have bvFTD and can as the disease progress, develop parkinsonism, thereby the 
previous name “FTD with parkinsonism linked to chromosome 17”. Neuropathological 
examination of MAPT mutation carriers reveals FTLD-tau pathology 
11, 38, 42-44
.  
 
Chromosome 9 open reading frame 72 – C9orf72 in FTD 
Unlike TARDBP and FUS, where the majority of mutations have been identified in 
patients with ALS, mutations in the C9orf72 gene have been detected in a substantial 
number of patients in both disease groups with a frequency of 11-25 % in familial FTD 
patients and 23-47 % in patients with familial ALS 
22, 24, 45, 46
. The C9orf72 protein is 
uncharacterized but has been shown to be expressed in the brain. There are two major 
C9orf72 transcripts and the mutation, which is a hexanucleotide repeat (GGGGCC) 
expansion, is located in the promoter region in one of the major transcripts and in the 
other major transcript the expansion is located in the intronic region. A minimum of 60 
repeats are suggested to be pathogenic while ≤25 repeats are considered to be non-
pathogenic 
22, 24, 45-47
. There have been reports indicating that C9orf72 mutation carriers 
in each following generation have an even earlier age at onset suggesting that there is 
anticipation. However, this has not been shown in all investigated families 
24, 47, 48
. 
Furthermore, the penetrance of the C9orf72 mutations is reduced but is estimated to be 
~100 % at the age of 80 years 
46
. The disease mechanism of C9orf72 mutations is being 
investigated and it has been shown that the C9orf72 transcript carrying the pathogenic 
expansion in its promoter region cannot be detected by real-time polymerase chain 
reaction (RT-PCR). In vitro models have demonstrated that the other major transcript 
with the hexanucleotide repeat expansion in its intronic region, forms ribonucleic acid 
(RNA) foci in the nucleus 
22, 45
. The majority of patients with C9orf72 mutations have 
bvFTD and 27-36 % of the patients also have ALS 
22, 24, 45, 46
. Neuropathological 
examination of C9orf72 mutation carriers reveals primarily FTLD-TDP type B 
pathology in the neocortex and hippocampus and in those cases where the patient has 
both FTD and ALS, TDP-43 inclusions in the lower motor neurons are detected. 
However, there are NCI that are not immunoreactive for TDP-43 indicating that there 
are other unidentified aggregated proteins 
45, 47
.   
 
Progranulin – GRN  
The FTD gene that has been investigated in this thesis is GRN. GRN mutations are 
present in 5-10 % of all FTD cases and 13-25 % of the familial cases 
18, 44, 49
. To date, 
69 mutations have been reported in GRN and they have been detected in all coding 
exons except for exon 13 (http://www.molgen.ua.ac.be/FTDMutations). The types of 
mutations detected are foremost nonsense, frame shift (deletions and insertions) and 
substitutions (missense and mutations affecting splice sites) but also deletions of the 
whole gene have been reported in two families 
50, 51
. The majority of the detected 
mutations results in a premature stop codon and it is hypothesized that the GRN 
messenger RNA (mRNA) carrying the mutation is degraded by nonsense mediated 
decay while the wild type GRN mRNA becomes translated. Thus, these null mutations 
would lead to an ~50 % reduction of functional GRN protein which can be measured in 
e.g. serum, plasma and cerebrospinal fluid 
52-55
. The mean age at onset for GRN 
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mutation carriers is around 60 years (ranging from 35 to 89 years) which is generally 
later compared to MAPT mutation carriers. GRN mutations have reduced penetrance 
and it is estimated that ~90 % of the mutation carriers are symptomatic at the age of 70 
years. The majority of GRN mutation carriers have bvFTD and many of the patients 
also develop parkinsonism, and symptoms such as hallucinations and delusions are 
frequently reported. In addition, patients with other clinical diagnoses have been 
reported to carry GRN mutations such as corticobasal syndrome and Alzheimer disease 
(AD). However, these diagnoses have not been confirmed by neuropathological 
examination 
5, 42-44, 49
.  
 
Progranulin – function  
GRN is an ~8 kbp gene, consisting of 13 exons (Figure 2). It encodes a 593 amino acid, 
88 kDa secreted glycoprotein. GRN is mainly expressed in cells with high mitotic 
activity such as epithelial cells in the intestinal crypt and epidermal keratinocytes of the 
skin, and also in immunological tissue such as the spleen and lymph nodes 
56
. In the 
central nervous system GRN is expressed in microglia and neurons in e.g. 
hippocampus, Purkinje cells of the cerebellum and motor neurons 
56, 57
. GRN can be 
cleaved by extracellular proteases such as elastase to smaller 6 kDa peptides called 
granulins (granulin A-G). The protein secretory leukocyte protease inhibitor (SLPI) can 
bind to GRN and prevents it from getting cleaved by elastase 
58
. Furthermore, it has 
been shown that GRN can bind to the transmembrane protein sortilin, which can 
regulate the extracellular levels of GRN through endocytosis 
59
.    
GRN has been shown to be involved in e.g. tumorigenesis, wound repair, development 
and inflammation. Progranulin can in in vitro models stimulate processes that are 
important in tumor formation such as proliferation and inhibition of apoptosis. In order 
to aid the wound healing process, GRN expression is increased in fibroblasts and 
endothelial cells in the wound, which under normal conditions express little or no GRN. 
Furthermore, it seems that the precursor GRN protein and the granulin peptides have 
opposite functions in inflammation. GRN has mainly anti-inflammatory action where it 
can bind the receptor tumor necrosis factor-α (TNF-α) and inhibit the receptor’s 
downstream signaling pathways. The granulin peptides have pro-inflammatory action 
such as stimulation of interleukin-8 secretion 
57, 60
. To investigate the function of GRN 
in vivo, transgenic mouse models have been generated. The role of GRN in 
inflammation response is further demonstrated in Grn
-/-
 mice that have increased 
microgliosis and astrogliosis, and delayed recovery after bacterial infection 
61-64
. GRN 
and granulin-E have been shown to promote cell survival and neurite outgrowth in 
cultured rat cortical neurons and spinal cord motor neurons 
65
. Knocking down GRN 
mRNA expression in primary cultured mouse cortical neurons with silencing RNA 
resulted in sensitization of cells to stimuli, which promoted cell death 
66
.  
 
Figure 2. Schematic figure of the progranulin gene with its 13 exons. The grey boxes indicate 
the non-coding regions of the gene and the green boxes are the coding regions.  
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Heterozygous knockout mice (Grn 
+/-
) have no phenotype but homozygous knockout 
mice (Grn
-/-
) have in some studies shown aggression, anxiety and dysfunctional social 
interactions 
62, 63, 67
. Unlike FTD patients, no general atrophy of the cerebrum has been 
observed in the Grn
-/-
 mice 
61, 62, 64
. Furthermore, the majority of the mouse models do 
not have TDP-43 immunoreactive neuronal inclusions 
61-64
. However, one mouse 
model showed ub-immunoreactive inclusions that co-localized with lipofuscin 
granules. Lipofuscin is a marker for cellular aging in postmitotic cells e.g. neurons, and 
the increased lipofuscin granules in Grn
-/-
 mice indicates that their neurons age faster 
than wild type mice 
61
.  
 
Risk genes and factors 
There are no known environmental risk factors for FTD, only genetic risk factors have 
been reported 
5, 68
. In this thesis, three potential genetic factors have been investigated: 
APOE, rs5848 located in the 3’UTR of GRN and rs1990622 in linkage disequilibrium 
with TMEM106B. 
 
Apolipoprotein E – APOE  
The APOE gene located on chromosome 19q13.2 encodes a 299 amino acid long 
protein which has three major isoforms: e2, e3 and e4. Each isoform shows differences 
in protein structure and biological function 
69
. The ApoE protein has for instance a lipid 
binding domain and the different isoforms bind to lipids with different affinity, making 
it more or less efficient as a lipid transporter. In the central nervous system ApoE is a 
major transporter of lipids. In AD, the gene allele APOE ɛ4 is a recognized risk factor 
but its role in FTD is unclear 
70, 71
. The evidence for APOE as a risk factor for FTD has 
been inconclusive with reports on a positive association where ɛ4 allele carriers had a 
lower age at onset and reports on no association with age at onset 
72-78
. Since, GRN 
mutations have reduced penetrance there maybe genetic modifying factors for age at 
onset in mutation carriers. Investigating APOE in GRN mutation carriers gave a 
surprising result: GRN mutation carriers with APOE ɛ4 had a later age at onset 
compared to ɛ3 patients 42, 79. However, this effect has not been observed in all studies 
21, 80
.  
 
rs5848 – 3’UTR of GRN 
In 2008 a significant association was found between FTLD-TDP patients and rs5848, a 
SNP located in the 3’UTR of GRN. The frequency of patients homozygous for the 
minor allele T was significantly higher compared to control individuals. Furthermore, it 
was estimated that patients with the TT genotype of rs5848 had a 3.2 fold increased risk 
of developing FTLD-TDP compared to CC individuals. When the authors investigated 
possible explanations for the association it was found that rs5848 was located in a 
predicted binding site for the microRNA miR-659. MicroRNAs are small non-coding 
RNA molecules that can bind to mRNA and modulate the target mRNA’s translation. It 
was predicted that miR-659 would bind to this region more strongly in the presence of 
a T allele compared to C allele and thus be a more efficient inhibitor of GRN 
translation. Western blot analysis and enzyme-linked immunosorbent assays (ELISA) 
performed on brain tissue from patients with FTLD-TDP neuropathology demonstrated 
that rs5848 TT patients had significantly lower GRN protein levels compared with 
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rs5848 CC genotype patients. In vitro studies also showed that miR-659 could regulate 
GRN levels 
81
. Although, the association between the rs5848 TT genotype and 
increased risk for developing FTD has not been replicated in other studies 
82, 83
, one 
study showed that FTD patients homozygous for the T allele had lower plasma-GRN 
levels compared to CC carriers 
84
. Thus, it is possible that FTD patients homozygous 
for the T allele have an increased risk for FTD and this effect maybe due to the 
modulation of GRN protein concentrations. 
 
 rs1990622 – in linkage disequilibrium with TMEM106B 
Genome wide association studies (GWAS) on FTD have been considered risky since 
FTD is a very heterogeneous disease with different clinical, genetic and 
neuropathological subgroups. Finding common risk factors for all FTD subtypes using 
GWAS would therefore be difficult. However, in 2010 the first and only FTD-GWAS 
was published 
85
. In order to get a homogenous patient cohort the authors only included 
patients with the neuropathological diagnosis FTLD-TDP. The patient cohort consisted 
of 515 FTLD-TDP patients, 89 of whom carried GRN mutations. The analysis resulted 
in the detection of three SNPs, located within a 68 kbp region on chromosome 7p21.3. 
The SNPs were in linkage disequilibrium (LD) with the gene transmembrane protein 
106B (TMEM106B), which encoded an uncharacterized 274 amino acid protein. The 
top SNP was rs1990622 (p = 2 x 10
-4
) with the major allele T being the risk allele. The 
significant association was detected both in patients with and without GRN mutations. 
Furthermore, the T allele was associated with higher levels of TMEM106B mRNA 
expression in lymphoblastoid cell lines and frontal cortex, indicating that rs1990622 or 
other SNPs in LD with rs1990622 could regulate the expression. The increased 
TMEM106B expression levels were highest in the GRN mutation carrier group. Thus, 
GRN mutations might act upstream of TMEM106B expression and together with the 
risk allele T modify the disease progression 
85
. In 2011 there was an attempt to replicate 
the top SNPs from the FTD-GWAS but failed 
86
. The authors suggested that the reason 
could be due to the heterogeneous patient cohort. In the replication study, clinical FTD 
patients were included indicating that other neuropathological subgroups such as 
FTLD-tau were most likely present. Therefore, it could mean that the findings from the 
first FTD-GWAS were specific for FTLD-TDP patients. Finally, studies investigating 
the association between the top SNP rs1990622 and age at onset in GRN mutation 
carriers have been inconclusive 
52, 85, 87, 88
. 
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AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease 
where the upper (cortex) and lower (brain stem and spinal cord) motor neurons 
progressively degenerate. Symptoms of upper motor neuron degeneration are for 
example muscular spasticity and hyperreflexia, and lower motor symptoms are for 
example muscular atrophy and fasiculations 
89, 90
. ALS patients can either have spinal 
onset i.e. symptoms starting in the upper or lower limb, or bulbar onset where the 
patients develop dysarthria and dysphagia. The age at onset is generally 55-65 years for 
sporadic ALS (SALS). However, in patients with a positive family history (FALS) the 
age at onset is usually 10 years earlier. Except for age at onset, there are no clinical 
differences between SALS and FALS. The progression of the disease is often rapid and 
the patient usually dies within 2-5 years after disease onset due to respiratory failure or 
pneumonia 
89-91
. Furthermore, up to 50 % of the ALS patients also have cognitive 
dysfunctions and 5-15 % of ALS patients develops FTD 
3, 89-93
.  
 
NEUROPATHOLOGY 
Neuropathological findings characteristic for ALS are neuronal cytoplamic inclusions 
(NCIs) in the remaining motor neurons: bunina bodies, skein-like inclusions and Lewy-
body like inclusions 
16, 17, 90, 94
.  
 
 Bunina bodies: eosinophilic granular NCIs that are immunoreactive for cystatin 
C and transferring but not for ub.  
 Skein-like inclusions: filamentous NCIs which are immunoreactive for ub and 
TDP-43.  
 Lewy-body like inclusions: compact and spherical inclusions immunoreactive 
for ub and TDP-43.  
 
The majority of ALS patients (>90 %) have TDP-43 positive neuropathology. Bunina 
bodies, skein-like inclusions and Lewy-body like inclusions are found in both SALS 
and FALS 
90, 94
. Furthermore, patients with mutations in the superoxide dismutase 1 
(SOD1) gene have inclusions consisting of SOD1 protein and the majority of ALS 
patients with SOD1 mutations do not have TDP-43 pathology suggesting that these two 
different pathologies have different etiologies 
94-97
. 
 
ALS GENETICS 
The majority of ALS patients seem to be sporadic (SALS) and ~10 % have a positive 
family history. From meta-analysis data on monozygotic and dizygotic twin studies the 
heritability of SALS was estimated to be 0.61 i.e. 61 % of SALS is explained by 
genetics and 39 % is explained by environmental factors 
98
. The genetics of ALS is 
complex with more than 10 reported causative genes e.g. SOD1 
99
 and C9orf72, and 
several suggested susceptibility genes e.g. APOE and ataxin-2 (ATXN2) 
89-91, 100-104
.  
 
Superoxide dismutase 1 – SOD1 
Before the identification of mutations in C9orf72, the mutation frequency of SOD1 was 
the highest in ALS accounting for 10-20 % of all FALS cases and 2-7 % of SALS 
89-91, 
 10 
100, 101
. To date, 165 dominant and recessive mutations have been reported in all of its 
five exons and the majority of the reported mutations are missense mutations with 
reduced penetrance (http://alsod.iop.kcl.ac.uk). SOD1 mutation carriers have primarily 
spinal onset with a mean age at onset at 55 years 
105
. The gene is located on 
chromosome 21q22.11 and encodes a 154 amino acid cytosolic enzyme. Together with 
the ions Cu
2+ 
and Zn
2+
, SOD1 forms a subunit which in a pair makes up the active 
SOD1 homodimer enzyme. Its function is to catalyze the reduction of the superoxide 
anion to O2 and H2O2. The hypothesized disease mechanism for SOD1 mutations is that 
the SOD1 protein gains cytotoxic function but of what kind is currently unknown 
104, 
106
. 
 
Chromosome 9 open reading frame 72 – C9orf72 in ALS 
Approximately 23-47 % of all FALS and 4-21 % of SALS patients have mutations in 
the C9orf72 gene. In patients with both FTD and ALS, the mutation frequency was 
almost up to 60 %. C9orf72 mutation carriers have more often spinal onset than bulbar 
onset. However, bulbar onset is more frequent in C9orf72 mutation carriers compared 
to SOD1 mutation carriers. Furthermore, the mean age at onset is ~57 years (range 27-
80 years) which is similar to patients carrying SOD1 mutations. Neuropathological 
examination on ALS patients with C9orf72 mutations show TDP-43 immunoreactive 
inclusions in the brain and spinal cord but not all ub-immunoreactive inclusions stain 
positive for TDP-43 
22, 24, 45, 46
.  
 
TAR DNA-binding protein 43 – TARDBP  
We have investigated the TARDBP gene which encodes the protein found to be 
aggregated in the motor neurons in the majority of ALS patients called TDP-43 
16, 17
. 
Mutations in the TARDBP gene have reduced penetrance and are reported in 4-6 % of 
the patients with FALS and 0-2 % in SALS 
23, 25, 104
. So far, more than 40 dominant 
mutations have been reported and the majority are missense mutations located in the 
coding region of exon 6 (http://alsod.iop.kcl.ac.uk, http://bioinfo.hr/pro-mine/). The 
majority of mutation carriers have spinal onset with the mean age at onset at 54 years 
105
. However, the disease mechanism for the mutations has not been determined.  
 
TAR DNA-binding protein 43 – structure and function 
TAR DNA binding protein 43 (TARDBP) is an ~13 kbp gene consisting of six exons 
(Figure 3).  It encodes a ubiquitously expressed 414 amino acid, 43 kDa nuclear protein 
that can bind to DNA and RNA. At the N-terminal of TDP-43 lies the nuclear 
localization signal and at its C-terminal lies the nuclear export signal. Its function is not 
completely understood but has been shown to be important in RNA metabolism e.g. in 
mRNA splicing, stability and transport. TDP-43 has e.g. been shown to regulate the 
splicing of exon 9 in the cystic fibrosis transmembrane conductance regulator gene  
 
 
 
 
 Figure 3. Schematic figure of the TARDBP gene with its 6 exons. The 
grey boxes indicate the non-coding regions of the gene and the green 
boxes are the coding regions.  
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(CFTR) and stabilize the low molecular weight neurofilament mRNA 
107-110
. The 
majority of normal endogenous TDP-43 is localized in the nucleus but there is a 
continuous shuttling of the protein between the nucleus and cytoplasma. However, in 
the pathological state the protein is instead translocated to the cytoplasma where it 
aggregates. The discovery of neuronal inclusions positive for TDP-43 was first made in 
FTLD and ALS 
16, 17
. Soon after, TDP-43 was also detected in other neurodegenerative 
disease such as AD (23-42 %) and Lewy body dementia (45-52 %) 
111-113
. In 
immunblot analyses using TDP-43 antibodies, two bands at ~25 kDa and ~35 kDa can 
be detected in the brain and spinal cord tissue extracts of FTLD-TDP and ALS patients 
and not in neurological healthy individuals 
16, 17
. These TDP-43 positive fragments can 
also be detected in transgenic mice that over-express human wild type TDP-43 or TDP-
43 with mutations 
114-117
. It is suggested that the C-terminal cleavage of TDP-43 is 
mediated by caspases, in particular caspase-3 
66, 118-120
. The pathologically aggregated 
TDP-43 has been shown to be not only ubiquitinated but also abnormally 
phosphorylated at the C-terminal positions Ser409/Ser410. There are now 
commercially available antibodies that target these phosphorylated sites and thus only 
bind to the pathological and aggregated forms of TDP-43 
121
.  
 
Different transgenic mouse models have been generated such as mice expressing 
human TARDBP with known mutations and mice over-expressing human TARDBP. 
These mice developed severe motor phenotypes similar to ALS patients such as 
weakness, spasticity, reduced spontaneous movements and shorter survival compared 
to wild type mice. Other features that the mouse models shared were that the severity of 
the symptoms, astrogliosis, microgliosis and neurodegeneration depended on the TDP-
43 expression levels i.e. it was dose-dependent. Ub-positive staining has been found in 
specific neurons such as the cortical neurons in layer V and in the motor neurons of the 
ventral horn in the spinal cord. The ub-positive cytoplasmic inclusions were in some 
transgenic mouse models also positive for TDP-43 but the majority was not 
114-117
. 
However, it has also been shown that over-expression of human TARDBP, with or 
without mutations, leads to down regulation of the endogenous mouse TDP-43 protein. 
This suggests that it might be possible that the loss of endogenous TDP-43 contributes 
to the neurodegeneration 
114
.  The importance of endogenous TDP-43 was shown by 
the fact that knocking out the mouse Tardbp gene was embryonic lethal 
122
.  
 
Since FTD patients with GRN mutations have FTLD-TDP neuropathology it indicates 
that there is a connection between these genes. Various in vitro studies using primary 
cortical mouse neurons with either Grn knockout or knockdown techniques 
demonstrated that reduced Grn expression can lead to TDP-43 redistribution from the 
nucleus to the cytoplasma 
66, 119, 120
. In some models, the reduction in Grn levels 
resulted in increased caspase activity. However, caspase activity was not necessary for 
the formation of TDP-43 aggregates 
66, 119, 120
. Furthermore, not all studies showed that 
the reduction of Grn levels was enough to induce caspase-mediated cleavage of     
TDP-43 
118
.  
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THESIS OBJECTIVES 
The overall aim of this thesis was to perform genetic studies in two diseases that belong 
to the same disease spectrum, FTD and ALS, by investigating the mutation frequency 
and possible modifying effects of candidate genes.   
 
Paper I 
The aim of this study was to investigate if the Swedish Karolinska family carried a 
mutation in the GRN gene which causes dominantly inherited FTD.  
 
Paper II 
The aim of this study was to investigate if the SNP rs1990622 in LD with the 
TMEM106B gene can modify the age at onset for GRN mutation carriers and to 
investigate possible functional effects of the SNP. 
 
Paper III 
The aim of this study was to investigate the mutation frequency of the GRN gene 
among FTD patients from Sweden. Additional aims were to use serum to evaluate if the 
detected GRN variations are pathogenic and if the three potential modifying factors 
rs5848, rs1990622 and APOE are associated with age at onset and/or serum-GRN 
levels in FTD patients. 
 
Paper IV 
The aim of this study was to investigate the TARDBP mutation frequency among 
Nordic ALS patients. 
 
 
   13 
METHODOLOGICAL CONSIDERATIONS 
A detailed description of materials and methods can be found in Papers I-IV. Here 
follows a summary of the main materials and methods used. 
 
SUBJECTS – PATIENTS AND CONTROLS 
The FTD patients included in Papers I-III were recruited from Karolinska University 
Hospital, Department of Geriatric medicine. The diagnostic criteria for FTD was 
according to Neary et al. 1998 
1
. In Paper III patients diagnosed as unspecified 
dementia with frontal signs were also included. Patients given this diagnosis were 
patients who displayed heterogeneous clinical symptoms which did not correspond to a 
single dementia diagnosis. Usually these patients had memory difficulties, which would 
suggest an AD diagnosis, and predominant behavioral problems which would indicate 
an FTD diagnosis. Furthermore, patients with a neuropathological diagnosis and tau 
negative FTLD were prioritized in the selection of the patient cohort in Paper III. 
 
The ALS patients included in Paper IV were recruited from the Umeå University 
hospital and were diagnosed according to El Escorial criteria 
123
. Patients with a 
positive family history for ALS or FTD were prioritized in the selection of the patient 
cohort.  
 
Additional deoxyribonucleic acid (DNA) from blood-relatives was available for 
segregation analysis and for haplotype analysis in some cases (Paper I-IV). 
 
The control cohort consisted of neurologically healthy individuals with mini mental 
state examination scores ≥28 and was recruited from the Swedish National study on 
Aging and Care (http://www.snac-k.se). 
 
Informed consent was obtained for all participants. Approved local ethical permissions 
were obtained for all studies. 
 
SEGREGATION ANALYSIS 
A method to find out if a detected genetic variation is pathogenic is to perform a 
segregation analysis. Here DNA from additional family members, preferably both 
affected and healthy family members, are needed in order to see if the variation co-
segregates with the disease i.e. the variation should be present only in affected family 
members and not in healthy individuals. However, it is important to keep in mind that 
the penetrance for GRN and TARDBP mutations is reduced i.e. a child to a healthy 
parent can inherit the mutation and develop the disease. Furthermore, it is also possible 
that the mutation is not present in an affected family member due to the fact that they 
have a different clinical diagnosis or another etiology for the disease e.g. in Paper III 
there was a family with diverse clinical diagnoses where one individual who was 
diagnosed with multiple sclerosis did not carry the mutation while the family members 
diagnosed as AD, FTD and vascular dementia carried the mutation. Another important 
aspect is the presence of phenocopies i.e. a family member showing the same clinical 
symptoms as its mutation carrying relative but the disease is instead caused by other 
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unknown genetic or environmental factors. This could be the case for a patient 
diagnosed with FTD after several years of mano-depressive disease in Paper III. 
 
NEUROPATHOLOGICAL EXAMINATION  
It is not always easy to give the “right” diagnosis since many patients do not present the 
typical “text book” symptoms of a disease. In the case of FTD where the age at onset is 
generally below the age of 65 years and where behavioral changes can be interpreted as 
a psychiatric disorder, the patient can be misdiagnosed. Furthermore, during the course 
of the disease, the FTD patient can be mistaken for AD because some patients may 
develop memory problems. In order to get a definite diagnosis neuropathological 
examination is necessary. In Paper III, a GRN mutation carrier received the clinical 
diagnosis AD but was re-diagnosed to FTLD-TDP after the neuropathological 
examination. The neuropathological subgroup FTLD-TDP can be further divided into 
four subtypes. In Papers I and III neuropathological examinations were performed on 
GRN mutation carriers which included immunohistochemistry for TDP-43. Recently, 
there was an update and harmonization of FTLD-TDP subtype classification. 
Previously there were two different classification systems and in Paper I and Paper II 
the mutation carriers were all classified as type 3 
9
 which now corresponds to type A 
using the new classification system 
14
.  
 
GENETIC ANALYSIS 
Sequencing 
Pathogenic mutations are often located in the coding regions of a gene where they can 
affect the sequence, structure, function and/or expression of the encoded protein. 
Furthermore, the donor and acceptor sites for splicing are located at the intron-exon 
boundaries, making this region an important target for mutation screening. We have 
therefore targeted the exons and at least 20 intronic bases at the intron-exon boundaries 
for mutation screening of GRN and TARDBP (Paper I, III and IV). In order to obtain 
the sequence, the targeted regions (usually 300-500 bp) were amplified with AmpliTaq 
Gold® PCR master mix (ABI, Branchburg, NJ, USA). However, to amplify exons 5 
and 6 in GRN addition of Q-solution (Qiagen, Hilden, Germany) (Paper I) or the use of 
AmpliTaq® Gold 360 master mix (ABI, Foster City, CA, USA) (Paper III) was needed 
due to the high GC content of the sequence. The target regions were sequenced using 
BigDye
®
 Terminator v.3.1 Cycle Sequencing Kit (ABI, Austin, TX, USA) and then 
analyzed on an ABI 3100 genetic analyzer in our laboratory (Figure 4).  
 
Figure 4. Electropherogram of the DNA sequence. The different peak colors of the electropherogram 
represent the different nucleotides. Here the black peak represents G, blue peak C, red peak T and 
green peak A.  
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Genotyping 
The genotype of the SNPs and microsatellites were obtained using three different 
methods:  
 The SNPs were genotyped using either sequencing or commercially available 
TaqMan
®
 SNP genotyping assays (ABI, Foster City, CA, USA).  
 When sequencing you automatically get information about SNP 
genotypes located in the target regions. In Paper III this method was 
useful since all of the studied SNPs in GRN could be obtain at the same 
time as the gene sequence. 
 TaqMan assay is a much faster method for genotyping compared to 
sequencing, especially if you are only interested in one specific SNP 
(e.g. rs1990622 in Paper II and III). The results were analyzed on ABI 
7500 Fast real-time PCR system. 
 Microsatellite markers are short runs (usually <100 bp) of tandem repeats of a 
few bases, usually 1-4 bp. The number of repeats for a specific microsatellite 
varies and therefore the numbers of alleles for the microsatellites are usually 
more than two. The number of repeats i.e. the length of the microsatellites can 
be determined by fragment length analysis using an ABI 3100 genetic analyzer. 
In Paper III, microsatellites flanking the GRN gene were genotyped in order to 
determine kinship between families with the same GRN mutation. The greater 
the shared disease haplotype are between two families the closer they are 
related. However, in Paper III we could not determine if the disease haplotype 
in the families that carried the same mutation were identical by state (have the 
same mutation but are not related) or by descent (have the same mutation 
because they have a common ancestor).  
 
MUTATION NOMENCLATURE 
The nomenclature of the detected genetic variations can be named depending on which 
level you want to describe the mutation on and the numbering is relative to a reference 
sequence:  
 
 g. = indicates that the description is at the genomic level. Number 1 is the first 
nucleotide of the genomic reference sequence.  
 c. = indicates that the description is at the cDNA level. Number 1 is the A in the 
translation initiation codon ATG of the cDNA reference sequence. 
 p. = indicates that the description is at the protein level. Number 1 is the 
translation initiation amino acid Methionine of the protein reference sequence.   
 
In Papers I-IV, the nomenclature describing the mutation’s consequence in the c.DNA 
and protein sequence has been primarily used. The changed nucleotides are indicated 
by the bases: Adenine (A), Cytosine (C), Guanine (G) and Thymine (T). Below are 
examples on mutations identified in this thesis and the interpretation of the mutation’s 
name: 
 
 c.543+59A>G: The nucleotide change is in the noncoding region of the gene. 
The closest coding nucleotide relative to the nucleotide substitution is number 
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543 which, in this case is the last nucleotide of an exon, and the 59
th
 nucleotide 
into the noncoding sequence is a transition from an A to G.  
 c.1069G>C  p.Arg361Thr: at nucleotide number 1069 in the coding sequence 
the wild type G has been changed to C. This genetic change results in a change 
in the protein sequence at amino acid number 361 where the wild type amino 
acid Arginine (Arg) has been changed to Threonine (Thr). 
 c.102delC  p.Gly35GlufsX10: The nucleotide number 102, which is a C, in 
the coding sequence has been deleted. This change in the coding sequence 
result in a frame shift (fs) and the amino acid at position 35 changes from 
Glycine (Gly) to Glutamic acid (Glu). The frame shift leads to a stop codon (X) 
at the 10
th
 codon from the initial amino acid change. 
 
BIOINFORMATICS 
A method to determine the consequence of a genetic variation is to perform in silico 
analysis. In Papers III and IV, splice site prediction programs and programs predicting 
the degree of pathogenicity of an amino acid substitution were used. There are different 
algorithms for predicting the consequence of a genetic variation and that is why it is 
important to use different programs, especially for splice site prediction. Variations 
located in the intronic sequence can either have no deleterious effect or an impact on 
e.g. splicing by creating a new slice donor site. For missense variations, prediction 
programs use information for instance about the evolutionary conservation and the 
differences in physicochemical properties between the substituted amino acids to 
determine the degree of pathogenicity.  
 
FUNCTIONAL ANALYSIS 
Real-time PCR 
In Paper I, RT-PCR was used to assess the relative reduction of mutation carrier’s GRN 
mRNA levels compared to non-carriers. An important aspect when running RT-PCR is 
the selection of internal standards. It is important to choose an internal control that is 
stable in different individuals, not dependent on cell type and has a similar expression 
level as the target. The choice is vital to be able to interpret the results as an effect of 
the mutation and not the effect of the internal control. In order to overcome these 
problem two internal controls were chosen: β-actin which is a widely used internal 
control, and the ribosomal protein, large, P0 (RPLP0) which expression was shown to 
be stable in fibroblasts using gene expression data from Nagasaka et al. 2005 
124
. 
 
GRN ELISA 
To evaluate what the consequence of a potentially pathogenic mutation has on the 
protein is important because even if you see an effect in the mRNA it might not be 
reflected in the protein or vice versa. For example, the GRN mutation p.Ala9Asp did 
not result in any changes in GRN mRNA expression levels instead it was shown to 
impair GRN protein secretion since the mutation is located in the signaling peptide. 
Measuring the GRN concentration in plasma demonstrated ~50 % reduction in secreted 
GRN protein 
53, 79, 125
. The majority of GRN mutations result in haploinsufficiency of 
functional GRN protein. In Paper III, the GRN protein concentration in serum was 
   17 
measured using Progranulin human ELISA kit (Adipogen, Incheon, Korea) which has 
pre-coated wells with polyclonal antibodies. 
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ETHICAL CONSIDERATIONS 
For all studies local ethical permissions were obtained: 
 
 dnr 485/02: Sample collection  
 dnr 484/02: Genetic research – Alzheimer disease 
 dnr 2007/661-32 (addendum to dnr 484/02): Biochemical research   
 dnr 2007/1212-32 (addendum to dnr 484/02 and dnr 2007/661-32): 
Genetic research – other diagnoses including frontotemporal dementia 
 dnr 01-114: Data collection and genetic analyses on individuals from 
Swedish National study on Aging and Care  
 dnr 03-398: Genetic and biochemical research on ALS/MND/dementia 
 
Informed consent has been obtained for all the patients included in the studies. 
 
The thesis contains several ethical considerations since it includes genetic studies and 
studies on individuals who have developed dementia. The identities of the patients 
included in the studies are anonymous in order to protect the families. Another 
important reason is that a mutation screen performed for research purpose can be 
treated as a genetic test if the identity of the patient is revealed. The results from a 
genetic screen done in a research setting are not communicated directly to the 
participants. One reason is that there are individuals that are willing to participate in 
genetic research but do not want to know the results. However, there are families that 
have expressed their desire to have the information and in those cases the results can be 
communicated to the families in a clinical genetics setting which can offer genetic 
counseling. The question about genetic testing is complex especially since there are no 
cures for FTD and ALS. The ethical aspect concerning clinical genetic testing are 
several and important to keep in mind but will not be discussed further here more than 
that our research work is performed in close collaboration with the Genetics Unit at the 
Department of Geriatric medicine in the Karolinska University Hospital ensuring 
professional genetic counseling when requested.  
 
In Papers II and III possible modifying genes have been investigated. However, to use 
such information in a clinical setting is still too early since the roles of the modifiers 
have not been absolutely proven and more research is needed. Furthermore, most 
importantly, to carry a risk allele does not automatically mean that you will develop the 
disease and absence of a risk allele does not exclude the risk to develop the disease.  
 
Another important ethical question is that the subjects included in this thesis are 
patients with dementia and can therefore not themselves give informed consent which 
is instead obtained from a relative. In addition, it can be difficult to determine when a 
person is cognitively healthy enough to be able to give informed consent. However, in 
order to perform research on dementia we need to have samples from patients with 
dementia.  
 
To perform genetic studies you need DNA which is most commonly obtained from a 
blood sample where the invasiveness is relatively low. However, to study e.g. the 
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consequence of a mutation on the RNA or protein level, you may need samples from a 
more invasive source such as a skin biopsy. Furthermore, to perform studies using post-
mortem brain tissue is invasive and even the question about brain donation can be 
considered invasive. Thus, it can be ethically questionable if it is right to take invasive 
samples from a patient with dementia when it is his/her relative that has given the 
informed consent. However, in order to give a definite diagnosis neuropathological 
examination is needed. The examination is also important since it can also give 
valuable information about pathogenic processes e.g. the identity of the aggregated 
protein, i.e. TDP-43, in the neurons of FTD (including GRN mutation carriers) and 
ALS patients was first discovered in 2006. Soon after this finding, mutations in the 
TARDBP gene were detected and the protein functions are being intensely studied in 
order to gain knowledge about possible disease mechanism pathways.  
 
Research on FTD and ALS patients is conducted because the disease mechanisms are 
not known. Furthermore, there is a need for reliable predictive and diagnostic 
biomarkers and most importantly, a cure for these diseases. Therefore, it can be 
ethically justified to perform studies using samples from patients with dementia 
especially since they no longer can actively take part in the fight against their own 
disease.  
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RESULTS AND DISCUSSIONS 
Detailed descriptions of the results and discussions are found in Papers I-IV. 
Summaries of the studies are given here.  
 
STUDY I 
Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska 
Family. 
 
The Swedish Karolinska family has an autosomal dominant inheritance pattern of FTD 
with a mean age at onset of 53.3 years 
126
. Linkage analysis showed linkage to 
chromosome 17q21 where the MAPT gene is located. However, sequencing MAPT did 
not reveal any mutation 
127
 and immunohistochemical examination of family members 
did not show tau pathology 
126
. When it was discovered that mutations in GRN, a gene 
only ~1.6 Mbp upstream of MAPT, could cause FTD we decided to investigate GRN.  
 
Sequencing of the GRN gene resulted in the detection of a previously reported cytosine 
(C) deletion in exon 2, c.102delC, which leads to a frame shift and a premature stop 
codon, p.Gly35GlufsX19 (Figure 5). Segregation analysis of c.102delC showed that the 
variation was present in all affected individuals and absent in four healthy family 
members above the age of 70 years. However, the variation was present in six healthy 
family members, of whom four were below the mean age at onset for this family and 
two individuals were above the mean age at onset. This indicates that the c.102delC has 
reduced penetrance (Figure 6).  
  
To investigate the functional consequence of the frame shift variation, total fibroblast 
RNA was isolated from two individuals from the Karolinska family, one mutation 
carrier and one non-carrier, and five healthy control individuals who were gender and 
cell passage matched. The relative level of GRN RNA was measured with RT-PCR and 
showed that there was an ~50 % reduction of GRN mRNA in the mutation carrier 
compared to the non-carriers. When sequencing the cDNA of the mutation carrier, only  
 
 
Figure 5. Elecotropherogram of the DNA 
sequence on the GRN mutation c.102delC 
(arrow). The wild type sequence is on the 
first row and the sequence with the mutation 
is below.  
Figure 6. Cumulative penetrance curve for c.102delC 
mutation carriers in the Karolinska family. n = number 
of mutation carriers that have reached the age group.  
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the RNA strand without the c.102delC was observed, suggesting that the mutant 
mRNA has been degraded by nonsense mediated decay and thus resulting in an ~50 % 
reduction of GRN mRNA levels. 
  
Immunohistochemical investigation of two family members with FTD showed that they 
had neurites, neuronal cytoplasmic and intranuclear inclusions positive for TDP-43 
which are characteristic features of GRN mutation carriers, FTLD-TDP type 3 or  
type A according to new classification (Figure 7) 
14
. With these findings the c.102delC 
was concluded to be pathogenic and causing the disease in the Karolinska family.  
 
Six affected individuals in the Karolinska family have previously been clinically 
described (branch 1, Figure 8). Here six additional affected individuals in two 
generations were described (branch 2). The mean age onset for branch 2 was 54.8 years 
(range 50-58 years) and the duration was 8.2 years (range 4-13 years). In all patients the 
first sign of disease was psychiatric symptoms such as changes in personality and/or 
depression. As the disease progressed, all patients developed memory dysfunctions, 
loss of spontaneous speech and apraxia. Later in the disease, three of the patients 
developed gait disturbances and two of these cases also had dysphagia. Speech 
disturbances leading to progressive aphasia were present in both branches of the family.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Immunohistochemical staining with TDP-43 antibody in (a) the frontal cortex and (b) the 
granular cells of the dentate gyrus in hippocampus. TDP-43–positive neuronal intranuclear inclusion 
are indicated with broken arrows and TDP-43–positive neuronal cytoplasmic inclusions are indicated 
with arrows. Scale bar, 50 µm.  
Figure 8. Anonymized pedigree of the Karolinska family with 
branches 1 and 2. The filled diamonds are individuals diagnosed 
with FTD, and the clear diamonds are healthy individuals. The 
number inside the diamonds reflects the number of siblings. The ? 
represents unclear phenotype.  
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STUDY II 
Association of TMEM106B gene polymorphism with age at onset in granulin 
mutation carriers and plasma granulin protein levels. 
 
It is recognized that FTD is a heterogeneous disease with several clinical and 
neuropathological subgroups and is therefore suspected to have diverse genetic 
components. In an FTD-GWAS study consisting only of FTLD-TDP patients, an 
association between three SNPs, in LD, and age at onset was found. The SNP with the 
strongest significance was rs1990622 which was located ~6.9 kbp downstream and in 
LD with the gene TMEM106B. Furthermore, the association with age at onset was 
strongest among the GRN mutation carriers 
85
. In order to determine if rs1990622 can 
modify age at onset in GRN mutation carriers the SNP was genotyped in 50 mutation 
carriers (affected n = 27 and unaffected n = 23) from four families (Table 1). 
 
The correlation between age at onset and rs1990622 genotype was assessed using the 
Kaplan-Meier method and tested for significant differences using a Cox proportional 
hazards model (Figure 9). The analysis showed that patients homozygous for the risk 
allele A had a median age at onset 13 years earlier compared to patients who were 
heterozygous or homozygous for the minor allele G (p = 9.9 x 10
-7
).  
 
To investigate possible disease mechanisms for rs1990622 in FTLD-TDP, the levels of 
plasma-GRN were measured in 73 healthy individuals and six GRN mutation carriers. 
The association between plasma-GRN levels and rs1990622 genotype was studied by 
using analysis of covariance. In healthy individuals the plasma-GRN levels were higher 
and more variable (163 ± 61 ng/ml; range 76-314 ng/ml) compared to GRN mutation 
carriers (47 ± 13 ng/ml; range 42-70 ng/ml). A significant difference in mean plasma-
GRN levels was observed in the healthy elderly individuals where individuals 
homozygous for the A allele had the lowest plasma-GRN levels while heterozygous 
had intermediate plasma-GRN levels and individuals homozygous for the G allele had 
the highest GRN levels (p = 4 x 10
-4
) (Table 2). In GRN mutation carriers a similar   
 
 
Figure 9. Age at onset was analyzed for 
association with rs1990622 in 50 GRN mutation 
carriers by the Kaplan-Meier method and tested for 
significant differences using a Cox proportional 
hazards model. Patients homozygous for the major 
allele A had an earlier age at onset than the patients 
heterozygous and homozygous for the minor allele 
G (p = 9.9 x 10
-7
).  
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significant effect was observed  (AA genotype: 49 ± 10 ng/ml, range 40-66 ng/ml vs. 
AG genotype: 63 ± 10 ng/ml, range 56-71 ng/ml; p = 0.003).  
 
In the reported FTD-GWAS, rs1990622 was also shown to be associated with 
TMEM106B gene expression in lymphoblastoid cell lines and in frontal cortex from 
seven neurologically healthy individuals and 18 patients with FTLD-TDP suggesting 
that rs1990622 modifies the risk for FTLD-TDP through modulation of TMEM106B 
mRNA expression. However, this could not be replicated in our study where cDNA 
from frontal cortex of 40 individuals without clinical dementia were analyzed. It could 
be that in the FTD-GWAS the majority of analyzed RNA was isolated from FTLD-
TDP patients and in this study only healthy individuals were analyzed. Thus, in the 
FTD-GWAS the effect of rs1990622 on TMEM106B mRNA expression level was 
primarily found in FTLD-TDP. Furthermore, we investigated if rs1990622 had an 
effect on the GRN expression levels but no correlation was observed. This indicates that 
the association between rs1990622 and plasma-GRN levels was not caused by 
modifying the GRN mRNA expression levels.  
 
In summary, an association between age at onset for GRN mutation carriers and 
homozygous A allele carriers was observed. Furthermore, the genotype of rs1990622 
was shown to modulate the plasma-GRN levels in GRN mutation carriers and healthy 
non-carriers, with AA genotypes having significantly lower plasma-GRN levels 
compared to the other genotypes. However, the disease mechanism for this association 
is unclear since the modulatory effect was not explained by the levels of TMEM106B 
mRNA or GRN mRNA. 
 
STUDY III 
Novel progranulin mutations with reduced serum-progranulin levels in 
frontotemporal dementia. 
 
It has been reported that up to 50 % of all FTD patients have a positive family history 
of dementia. In order to investigate the importance of GRN mutations in our FTD 
cohort 100 patients with different FTD sub-diagnoses such as SD, PNFA, FTD-ALS 
and dementia with frontal signs were sequenced. The sequencing resulted in the 
detection of two missense variations (p.Arg432Cys and p.Arg433Trp) and four 
premature stop codon variations: two frame shift (p.Gly35GlufsX19 and 
p.Cys416LeufsX30) and two nonsense (p.Tyr294X and p.Cys404X). Of the detected  
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variations only the p.Arg433Trp was identified in one out of 171 neurologically healthy 
individuals.  
 
The p.Gly35GlufsX19 (p.Gly35fs) was detected in a patient diagnosed with primary 
progressive aphasia with an age at onset before 59 years (Table 3). This variation has 
previously been reported in the Karolinska family and haplotype analysis showed that 
these two families shared a disease haplotype of at least 297 bp. The result indicates 
that these two families are either very distantly related or that the p.Gly35fs mutation 
has arisen twice, i.e. either the disease haplotype is identical by descent or state.  
 
The p.Cys416LeufsX30 (p.Cys416fs) was detected in a patient who first was diagnosed 
with AD and later received the neuropathological diagnosis FTLD-TDP with type 3 
histology, corresponding to type A with the new classification 
14
 (Figure 10 a-c). The 
proband belonged to a family with a positive history for different types of dementia 
such as AD and vascular dementia. Segregation analysis was performed on additional 
affected (n = 6) and non-affected (n = 11) family members. All of the affected family 
members were shown to carry p.Cys416fs except for two patients: one diagnosed with 
multiple sclerosis and one patient who had suffered from mano-depressive disease from  
 
 
 
Table 3. Patients with potentially pathogenic variations in GRN.  
    
Patient 
ID 
Proteina 
rs5848 
genotype 
rs1990622 
genotype 
Serum GRN 
concentration 
(ng/ml) 
Age at 
onset 
(years) 
Age at 
death 
(years) 
Clinical 
subgroup 
Family historyb  
Neuropathological 
diagnosis 
A01 p.Arg432Cys  C/T A/A 117.7 58 69 
FTD or AD with 
parkinsonism 
No 
information  
B01 p.Gly35GlufsX19  C/T A/A 31.1 before 59 alivec PPA Yes 
 
C01 p.Cys416LeufsX30  C/T A/G 46.7d 64 71 AD Yes FTLD-TDP 
D01 p.Tyr294X  C/T A/A 42.2 54 58 PNFA Yes FTLD-TDP 
E01 p.Tyr294X  C/T A/A 44.0 69-70 76 bvFTD Yes 
 
F01 p.Cys404X  C/T A/G 
 
58 66 bvFTD 
No 
information  
FTD frontotemporal dementia; AD Alzheimer disease; PPA primary progressive aphasia; PNFA progressive non-fluent aphasia; bvFTD 
behavior variant FTD  
a The numbering is according to NP_002078.1 with methionine as amino acid 1.  
b Positive family history is defined as having dementia in at least one first degree relative or at least one second degree relative (including 
half siblings).  
c The information is current as of February 2012.  
d GRN concentration obtained from a family member with the same mutation.  
Figure 10. Immunohistochemical 
staining of the frontal cortex with 
TDP-43 antibody on the patient with 
the p.Cys416LeufsX30 mutation 
(figure 10 a-c) and the patient with 
p.Tyr294X mutation (Figure 10 d-f). 
TDP-43 immunoreactive neuronal 
cytoplasmic inclusions (arrows in 
figure a and d), neurites (arrows in 
figure b and e) and intranuclear 
inclusions (arrow in figure c and f) 
were detected in both patients. Scale 
bar, 20 µm.  
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his 30’s and later developed dementia and which was diagnosed as FTD at the age of 
81 years. The mean age at onset for the carriers was 65.2 years (range 55-71 years). Of 
the healthy family members, the p.Cys416fs was absent in eight individuals, of whom 
three were above the age of 75 years. One of the healthy relatives who carried the 
frame shift variation was above the mean age at onset indicating that p.Cys416fs has 
reduced penetrance (Figure 11). 
 
The p.Tyr294X was detected in two FTD patients with different clinical subtypes and a 
14 years difference in age at onset (Table 3). It was not possible to perform haplotype 
analysis on these two patients. However, genotyping seven GRN SNPs and the 
microsatellites flanking GRN showed that they shared alleles spanning from D17S1789 
to D17S792 which corresponds to an ~16.5 Mbp region. Neuropathological 
examination of one of the p.Tyr294X carriers resulted in the diagnosis FTLD-TDP with 
type 3 histology corresponding to type A (Figure 10 d-f) 
14
. 
 
It is known that GRN mutations have reduced penetrance which indicates the presence 
of modifying genes and one possible modifying gene is rs1990622 (see Study II). 
Investigating the SNP in patients carrying GRN mutations (n = 9) showed a trend of 10 
years earlier age at onset for patients with one or two A alleles compared to GG 
patients (59.6 ± 8.7 years and 69.5 ± 2.1 years respectively). However, since there were 
only nine mutation carriers, no robust statistical analysis could be performed. In 
contrast, analyzing rs1990622 in the total patient cohort did not reveal any correlation 
with age at onset. Another possible modifying gene is APOE and a significant 
difference in mean age at onset was detected between APOE ɛ4 negative and positive 
FTD patients (58.3 ± 8.4 years and 62.6 ± 7.2 years respectively) with a p value of 0.01. 
This finding is in contrast to previous studies where either an association to an earlier 
age at onset for ɛ4 positive patients has been reported or no association at all. However, 
it has previously been reported that GRN mutation carriers who were also positive for 
APOE ɛ4 had a later age at onset compared to ɛ4 negative carriers, which is in 
agreement with our observation 
42, 79
. 
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Figure 11. Penetrance curve of eight p.Cys416LeufsX30 carriers. 
The curve shows the percentage of mutations carriers that have 
developed the disease in an age group. n = number of mutation 
carriers that have reached the age group.  
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The serum-GRN levels were measured in 64 out of 100 FTD patients (Figure 11). 
Serum was available for all the detected variations affecting the amino acid sequence 
except for p.Cys404X. The serum-GRN levels were more than 50 % reduced in the 
premature stop codon carriers compared to patients that did not carry any premature 
stop codons, mean concentration of 41.7 ± 5.7 ng/ml (range 31.9-46.7 ng/ml) and  
139.7 ± 27.5 ng/ml (range 84.5-220.8 ng/ml) respectively (Figure 11). This suggests 
that the premature stop codon variations are pathogenic since they result in more than 
50 % reduction in serum-GRN. Furthermore, large variations in the serum-GRN levels 
were observed among FTD patients that did not carry premature stop codons. Possible 
modifying genes for the detected GRN level differences were investigated: rs5848, 
rs1990622 and APOE. Investigating these SNPs, only the rs5848 reached significance 
(p = 0.04). Patients homozygous for the minor allele T had significantly lower serum-
GRN concentration (120.0 ± 23.9 ng/ml) compared to CC and CT genotypes (138.9 ± 
24.5 ng/ml and 146.3 ± 28.1 ng/ml respectively). This is in agreement with previous 
reports where it was hypothesized that miR-659 could inhibit GRN translation more 
efficiently when it binds to the rs5848 T allele transcript compared to C allele.  
 
In summary, four GRN premature stop codon mutations were detected, where three 
demonstrated a more than 50 % reduction in serum-GRN levels. The GRN mutations 
also demonstrated clinical heterogeneity in patients with the same mutation. Three 
possible modifying factors for age at onset and GRN levels were investigated. The 
APOE showed significance for age at onset with ɛ4 positive patients having a later age 
at onset compared to ɛ4 negative patients. Furthermore, the genotype of rs5848 was 
associated with the serum-GRN levels with TT genotype having significantly lower 
levels compared to the other genotypes.  
 
STUDY IV 
Novel TARDBP mutations in Nordic ALS patients. 
 
In 2006 it was shown that the majority of ALS patients had TDP-43 immunoreactive 
neuronal inclusions. Thus, it was hypothesized that mutations in the TARDBP gene  
Figure 11. Serum progranulin protein concentrations in 64 FTD patients and additional family 
members of GRN mutation carriers and non-carriers. The “+” indicates mutation carrier and the “-“ 
indicates family members that do not carry the GRN mutation. The black line indicates the mean 
serum-GRN level, 139.7 ng/ml, of all FTD patients without premature stop codons (n = 61). The 
dashed line represents one and two standard deviations from the mean value, respectively. 
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Table 4. Summary of the clinical description of patients carrying missense variations in TARDBP.  
Patient 
ID 
Protein 
positiona 
Family 
history 
Nationality Diagnosis 
Age at onset 
(years) 
First symptom 
Survival 
(years) 
1:A 
  p.A90Vb   
Yes Danish ALS 67 Dysarthria  2 
  p.G357Rb, c  
2:Ad   p.R361Tc  Yes Norwegian ALS 69 Paresis in left leg  6 
2:Bd   p.R361Tc  Yes Norwegian FTD-ALS 66 Deficits in verbal fluency and memory  2 
3:A   p.S379P  Yes Danish ALS 62 Weakness in legs and difficulties with walking  3 
a The numbering is according to the longest amino acid sequence (ENSP00000240185) with Met as amino acid 1.  
b Both variations identified in the same individual.  
c Not previously reported.  
d 2:A and 2:B belong to the same family.  
 
could cause ALS. We therefore sequenced the TARDBP gene in 177 ALS patients from 
the Nordic countries and found several non-coding variations and four missense 
variations: p.Ala90Val, p.Gly357Arg, p.Arg361Thr and p.Ser379Pro (Table 4). None 
of the non-coding variations were predicted to affect the splicing except for 
c.543+59A>G. Three out of four splice site prediction programs predicted a new splice 
donor site in c.543+59A>G which would result in an 18 amino acid longer exon 4 
coded protein and end with a premature stop codon thereby excluding exons 5 and 6. 
However, no source for RNA and protein analysis was available for the functional 
analysis of c.543+59A>G. The c.543+59A>G was identified in a patient with spinal 
onset ALS at the age of 68 years. Segregation analysis in additional family members 
showed that the variation was present in one healthy relative but absent in a relative 
with ALS. This variation was absent in 200 neurologically healthy individuals. Thus, 
the pathogenic nature of c.543+59A>G is unclear.  
 
The four missense variations were detected in three FALS patients and absent in 200 
neurologically healthy control individuals. The two missense variations p.Ala90Val and 
p.Gly357Arg were present in the same patient who developed bulbar onset ALS at the 
age of 67 years (Table 4). Segregation analysis in six healthy family members of whom 
four were above the age of 70 years, showed that two of the relatives between the ages 
of 50-70 years carried either of the two missense variations. There was also one family 
member above the age of 70 years who carried both p.Ala90Val and p.Gly357Arg, and 
was still healthy. The p.Ala90Val has previously been reported in healthy individuals in 
a higher frequency than in ALS patients indicating that this variation might be a rare 
but non-pathogenic variation. However, in vitro data indicates that p.Ala90Val might 
impair the shuttling of TDP-43 between the cytosol and the nucleus since the variation 
is located in the nucleus localization signal. Thus, it is possible that p.Ala90Val has a 
modifying effect on TDP-43 as a risk factor but cannot alone cause ALS. The other 
missense variation found in the patient, p.Gly357Arg, was predicted to be pathogenic 
by bioinformatics. Thus, it is possible that p.Gly357Arg caused the disease in the 
family, and p.Ala90Val acts as a modifying risk factor.  
 
The p.Arg361Thr was detected in a patient who developed spinal onset ALS at the age 
of 69 years (Table 4). Segregation analysis demonstrated that the variation segregated 
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with the disease. In addition, there was a relative who developed FTD at the age of 66 
years and as the disease progressed, also developed ALS. Thus, p.Arg361Thr is likely 
pathogenic and can cause both ALS and FTD-ALS.  
 
The fourth and last missense variation, p.Ser379Pro, was detected in an ALS patient 
with spinal onset at the age of 62 years (Table 4). Segregation analysis could not be 
performed and the variation was not detected in the healthy control cohort. This 
variation has previously been reported to be pathogenic which was also our conclusion. 
 
Taken together, the mutation frequency of TARDBP in our ALS cohort was 1.7 % 
which is low compared to other reports (FALS ~5 %) and considering that the cohort 
was selected with the preference of patients with a positive family history, indicates 
that mutations in TARDBP are a rare cause for ALS in the Nordic countries.  
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CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
In this thesis, genetic analyses have been performed on FTD and ALS patients. The 
genetics of FTD has been investigated with respect to GRN mutation frequency and 
possible modifying genes. In Paper I, the mutation responsible for the disease in a 
family with dominantly inherited FTD showing linkage to chromosome 17 was finally 
identified in the GRN gene. The varied age at onset in this and other GRN mutation 
families raised the question about possible modifying genes. Possible modifying SNPs 
in LD with the gene TMEM106B were discovered in the first published FTD-GWAS. 
In Paper II the top SNP, rs1990622, was investigated in four families with GRN 
mutations. It was shown that patients homozygous for the risk allele had a significantly 
lower age at onset compared to the other genotypes. Additional investigation on 
possible functional effects of the SNP was performed and demonstrated that the risk 
allele could modify the GRN protein levels in plasma.  
 
In Paper III the mutation frequency of the GRN gene and three possible disease 
modifying factors (rs1990622, rs5848 and APOE) were investigated in 100 patients 
with different FTD subtypes. The mutation screening revealed a 4 % mutation 
frequency in patients with FTD in Sweden. The initial idea of replicating the 
association between age at onset and rs1990622 from Paper II was not possible because 
the numbers of patients carrying GRN mutations were too few to perform statistical 
analysis. However, investigating the three SNPs in the whole FTD patient cohort 
reveled that patients positive for the APOE ɛ4 allele had a significantly later age at 
onset compared to ɛ4 negative patients. This finding has previously been reported in 
GRN mutation carriers, but the possible protective mechanism of ɛ4 allele is unknown. 
The three SNPs’ effect on serum-GRN levels were studied and we could not replicate 
our finding from Paper II where rs1990622 were shown to modify GRN protein levels. 
However, we did observe that rs5848 could modify the GRN levels, where patients 
homozygous for the T allele had significantly lower serum-GRN levels compared to the 
other genotypes. This finding is in line with previous reports about the rs5848 being a 
binding site for miR-659 which can influence the GRN translation. 
 
It is recognized that FTD and ALS are part of the same disease spectrum. The largest 
neuropathological FTLD subgroup has TDP-43 positive neuronal inclusions, including 
GRN mutation carriers, and the majority of ALS patients also have TDP-43 
immunoreactive neuronal inclusions. In Paper IV, the mutation frequency of the gene 
encoding TDP-43, TARDBP, was investigated in ALS patients from the Nordic 
countries. From our mutation screen it was concluded that mutations in TARDBP is a 
rare cause for ALS, representing 1.7 % of the Nordic ALS patients in our cohort. 
Furthermore, one of the detected mutations was present in a family with both ALS and 
FTD-ALS which further strengthens the connection between the two diseases. 
 
The findings from Study I-IV show that there are still unidentified genetic factors that 
can contribute or cause FTD and/or ALS. A recent finding in 2011, was the 
identification of C9orf72 mutations in high frequency in patients with FTD, FTD-ALS 
and ALS and has therefore prompted us and other groups to investigate the gene in 
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respective patient cohorts. We have in collaboration with international groups included 
73 patients from Sweden (FTD n = 64; FTD-ALS n = 7; ALS n = 2) for C9orf72 
mutation screening. The preliminary results indicate that 19 of the 73 patients carry the 
hexanucleotide expansion (FTD n = 14; FTD-ALS n = 4; ALS n = 1), which 
corresponds to a mutation frequency of 26 %. This preliminary data suggests that 
mutations in C9orf72 are the most common known cause of FTD and FTD-ALS 
patients in Sweden. 
 
Even with the identification of mutation in C9orf72 there are still other unknown genes 
with pathogenic mutations and modifying effects on disease course (age at onset and 
survival) and clinical phenotype. New FTD-GWAS is ongoing and it will be interesting 
to see what the results will be. Furthermore, the rapid use of new methods such as next 
generation sequencing, which makes it possible to sequence the whole genome and 
exome, opens up new opportunities to find disease causing mutations in unknown 
genes, and challenges in handling and interpreting all the generated information.  
 
There are still no cures for FTD or ALS. However, for patients with GRN mutations 
there are investigation for proteins that can increase the GRN levels. The proteins that 
are currently used clinically for other diseases have been shown in vitro to elevate the 
GRN protein levels by up-regulating the transcription or the translation of GRN 
128, 129
. 
It is still too early to predict the outcome of these drugs since they have not been tested 
in vivo. If there is an effective and safe drug that can elevate the GRN levels to the 
normal, genetic testing can be used to target the patients with GRN mutations and give 
the drug before the neurodegeneration occurs. 
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